Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Tumor ecosystems

Sarcoma ecotypes determine immunotherapy benefit

Nature Cancer volume 5, pages 536–538 (2024)Cite this article

Subjects

Sarcomas are heterogeneous connective tissue tumors that occur at various anatomic sites and are generally difficult to treat. Cell states in sarcoma ecosystems are now shown to be conserved across multiple subtypes and associated with response to immunotherapy and patient outcome.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Using machine learning to characterize the cellular composition of STS based on gene expression.

References

  1. Burningham, Z., Hashibe, M., Spector, L. & Schiffman, J. D. Clin. Sarcoma Res. 2, 14 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  2. van der Graaf, W. T. A., Tesselaar, M. E. T., McVeigh, T. P., Oyen, W. J. G. & Fröhling, S. Semin. Cancer Biol. 84, 228–241 (2022).

    Article  PubMed  Google Scholar 

  3. Suehnholz, S. P. et al. Cancer Discov. 14, 49–65 (2023).

    Article  PubMed Central  Google Scholar 

  4. Horak, P. et al. Cancer Discov. 11, 2780–2795 (2021).

    Article  CAS  PubMed  Google Scholar 

  5. Jerby-Arnon, L. et al. Nat. Med. 27, 289–300 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wei, Y. et al. Nat. Cancer 3, 961–975 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. DeMartino, J. et al. Nat. Commun. 14, 3074 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Danielli, S. G. et al. Sci. Adv. 9, eade9238 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yuan, L. L. et al. Front. Immunol. 13, 1019870 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. , A. et al. Nat. Cancer https://doi.org/10.1038/s43018-024-00743-y (2024).

  11. Luca, B. A. et al. Cell 184, 5482–5496.e28 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Newman, A. M. et al. Nat. Biotechnol. 37, 773–782 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Petitprez, F. et al. Nature 577, 556–560 (2020).

    Article  CAS  PubMed  Google Scholar 

  14. Italiano, A. et al. Nat. Med. 28, 1199–1206 (2022).

    Article  CAS  PubMed  Google Scholar 

  15. Tawbi, H. A. et al. Lancet Oncol. 18, 1493–1501 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany

    Johanna Wagner & Stefan Fröhling

  2. National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany

    Johanna Wagner & Stefan Fröhling

  3. German Cancer Consortium (DKTK), Heidelberg, Germany

    Stefan Fröhling

  4. Institute of Human Genetics, Heidelberg University, Heidelberg, Germany

    Stefan Fröhling

Authors
  1. Johanna Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Fröhling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Fröhling.

Ethics declarations

Competing interests

S.F. reports consultancy fees from Bayer, Illumina and Roche; honoraria from Amgen, Eli Lilly, PharmaMar and Roche; research funding from AstraZeneca, Pfizer, PharmaMar and Roche; and travel or accommodation expense reimbursement from Amgen, Eli Lilly, Illumina, PharmaMar and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wagner, J., Fröhling, S. Sarcoma ecotypes determine immunotherapy benefit. Nat Cancer 5, 536–538 (2024). https://doi.org/10.1038/s43018-024-00762-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-024-00762-9

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer